Renal Business Today

Weak Link Between Certain Biomarkers, Cardiovascular Risks in CKD

CHICAGO—Even though clinical practice guidelines for patients with chronic kidney disease recommend specific treatment target levels for serum phosphorus, parathyroid hormone, and calcium to reduce the risk of cardiovascular events, an analysis of data from previous studies ...More

March 16, 2011

Posted in News, Clinical & Pharma

Cutting Dietary Phosphate Doesn't Extend Dialysis Patients' Lives

WASHINGTON—Doctors often ask kidney disease patients on dialysis to limit the amount of phosphate they consume in their diets, but this does not help prolong their lives, according to a study published online Dec. 9 in the Clinical Journal of the American Society Nephrology ...More

December 10, 2010

Posted in News, Clinical & Pharma

Keryx Completes Phase 3 Enrollment for Zerenex

NEW YORK—Keryx Biopharmaceuticals announced that the randomization of the last patient in its short-term study component of its phase 3 registration program of Zerenex (ferric citrate). ...More

October 28, 2010

Posted in News, Clinical & Pharma, Government & Regulation

Processed Foods with Phosphorus Additives May Contribute to CKD

WASHINGTON—Processed and fast foods enriched with phosphorus additives may play a role in health disparities in chronic kidney disease, according to a study appearing online Sept. 16 in the Journal of the American Society of Nephrology (JASN). ...More

September 16, 2010

Posted in News, Clinical & Pharma

DaVita Launches Online Phosphorus Challenge

DENVER—DaVita Inc. has launched the DaVita Phosphorus Challenge, which is an online resource designed to serve as a core learning tool for chronic kidney disease and dialysis patients ...More

April 27, 2010

Posted in News, Business, Clinical & Pharma

Medical Directors Concerned About Bundle, Patient Outcomes

EXTON, Pa.—Medical directors report a significantly higher awareness of the dialysis bundle and have become decidedly more negative about the impact to patient outcomes, according to new results released March 24 by BioTrendsResearch Group. ...More

March 24, 2010

Posted in News, Business, Clinical & Pharma, Government & Regulation, Practice Management

Genzyme Ends Development of Renvela Successor

CAMBRIDGE, Mass.—Genzyme Corp. said Nov. 18 that it has ended the development of a new phosphate binder for dialysis patients because the new drug did not work much better than its existing drug Renvela. ...More

November 18, 2009

Posted in News, Business, Clinical & Pharma

Genzyme Launches Renvela Powder in U.S.

CAMBRIDGE, Mass.—Genzyme Corp. announced Nov. 10 that it has launched a powder form of its phosphate binder Renvela in the United States. ...More

November 10, 2009

Posted in News, Business, Clinical & Pharma

Higher Phosphorus Levels Raise Heart Disease Risk

WASHINGTON—Higher levels of phosphorus in the blood are linked to increased calcification of the coronary arteries— a key marker of heart disease risk, according to a study appearing online Nov. 5 in the Clinical Journal of the American Society of Nephrology. ...More

November 5, 2009

Posted in News, Clinical & Pharma

Shire Publishes Study Comparing Fosrenol, Renagel

Shire has published in Clinical Nephrology findings from a head-to-head clinical study comparing the efficacy of two non-calcium based phosphate binders, Fosrenol (lanthanum carbonate) and sevelamer hydrochloride (Genzyme's Renagel) in chronic kidney disease (CKD) patients ...More

October 7, 2009

Posted in News, Business, Clinical & Pharma

Computers & Software	Consulting, Management...
Equipment & Services	Hemodialysis Supplies
Patient Services	More Options...

Phosphorus

Mobile Health Snaps

Galleries

Most Popular Articles

Buyer's Guide

Resources

Free Email Updates

featured links

First Name	Last Name
E-Mail